Landscapes / Companies
Alentis Therapeutics AG not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
3 in Phase 2
Drugs
3
in active trials · 4 in all
Trials
3 active
5 since 2021
Drugs3
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 2 | 30 Jun 2027Phase 2 trial completes | |||
| Next date | 30 Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Glomerulonephritis Rapidly Progressive | ||||
| Open drug page | |||||
— |
Phase 1/2 | 15 Feb 2028Phase 1/2 trial completes | |||
| Next date | 15 Feb 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 5 Apr 2029Phase 1/2 trial completes | |||
| Next date | 5 Apr 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer and 3 more | ||||
| Open drug page | |||||
About
- No active trial
- ALE.C04
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021